Transcode Therapeutics (NASDAQ: RNAZ) stock was up 200% yesterday. RNAZ stock rose on the news that one of their treatments has positive results in a brain cancer trial. This is clearly value additive to the company - it’s probably value additive to society as well. So, this is good: “the company announced positive results with its TTX-MC138, in murine models bearing human glioblastoma multiforme or GBM tumors. In this study, the therapeutic candidate was delivered to GBM brain tumors, the most common and aggressive form of brain cancer, and effectively engaged its target.” There are reasons to think that it might also work on breast and other cancers as well. OK, that’s what development pharma is all about.
This also might explain the volatility of Transcode stock: “Transcode Therapeutics (NASDAQ: RNAZ) stock is up 80% premarket this morning. RNAZ stock is also down around 50% from its peak a few days back. So, it’s fair to say that there’s a certain amount of volatility here. That’s also fair enough for the company has filed to issue more stock but as yet we don’t seem to know the price they’re going to try and issue at. That’s what also contains a certain danger for us. Any increase in the RNAZ stock price here will increase the likely issuance price - making it more expensive for us to buy in even as - because of - it’s less dilutive to current shareholders.”
The issue here is how development pharma stocks fund themselves. Until there’s an FDA licence for something there’s no asset. So there’s nothing to lend against - all costs must be met by stockholder capital. Well, that’s OK, as long as we know. This can take a long time with a few bumps along the way, as the RNAZ reverse stock split in the spring shows us. But this then gives us one more thing to think about.
Transcode Therapeutics stock price from Google Finance
But no one funds a company right through the 10 year development period of a new treatment. It’s always here’s some capital, enough to get to the next make or break stage of the testing. Only if it passes the test do we then put more capital in to take it to the next stage. The obvious corollary of this is that when a test is passed - as here - the stock price will rise and that’s when the new stock issue is.
As we’ve a new stock issue here: “underwritten public offering of an aggregate of 15,700,000 shares of its common stock (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof). Each share of common stock (or Pre-Funded Warrant) is being sold at a public offering price of $0.51 per share (inclusive of the Pre-Funded Warrant exercise price of $0.01).” At the price before this news, around $0.66 cents, this would have been a reasonable new issue price. At the post-news price, $2, this is not a good price from the point of view of the company. Rather too cheap and very dilutive.
There’s a strong thought that Transcode should have waited a few more hours before pricing this stock issue. It’s possible to think that they’ve left a lot of money on the table. We’d also expect, given the size of the issue and the price, that there’s going to be a significant reversal in that stock price in 3…2…1..